Skip to search formSkip to main contentSkip to account menu

Sulfinpyrazone

Known as: Sulphinpyrazone, 3,5-Pyrazolidinedione, 1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)-, Sulfoxyphenylpyrazolidine 
A phenylbutazone derivative with uricosuric and antithrombotic properties. Sulfinpyrazone competitively inhibits reabsorption of urate at the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
BACKGROUND End-stage renal disease (ESRD) patients often require either the formation of an arteriovenous (AV) fistula or an AV… 
Highly Cited
1996
Highly Cited
1996
Objective: In several systems, exogenous ascorbate (reduced vitamin C) has been shown to protect against microvascular injury… 
1982
1982
Summary Forty-seven patients presenting with acute chest pain had in vivo platelet activity assessed by measuring plasma levels… 
Highly Cited
1979
Highly Cited
1979
Summary The ability of potential anti-thrombotic agents to modify platelet-thrombus formation in injured cerebral arteries in the… 
Highly Cited
1978
Highly Cited
1978
Synthesis of prostaglandin I2, (PGI2, prostacyclin) by vascular endothelium (assayed by the ability of cultured endothelial cells… 
Highly Cited
1975
Highly Cited
1975
The effect of sulfinpyrazone on the incidence of thrombosis of arterio-venous shunts was investigated in a double-blind crossover… 
Highly Cited
1967
Highly Cited
1967
Platelet survival was prolonged in rabbits which had been on sulfinpyrazone for 30 days or more. This was not accompanied by…